Nanobiotix S.A. NANO.PA · Stock Open Nanobiotix S.A. in new tab
Analyst price targets
Recent rating changes, newest first
Nanobiotix S.A. Analysis (NANO.PA)
Is Nanobiotix S.A. a good investment? Nanobiotix S.A. (NANO.PA) is currently trading at 19.56 EUR. Market analysts have a consensus price target of 52.20 EUR. This suggests a potential upside from current levels.
Earnings Schedule: Nanobiotix S.A. is expected to release its next earnings report on April 27, 2027. The market consensus estimate for Forward EPS is -0.25.
Investor FAQ
Does Nanobiotix S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Nanobiotix S.A.?
Nanobiotix S.A. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 27, 2027. The company currently has a trailing EPS of -1.09.
Company Profile
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 25, 2014 | 1.09 |
Community Discussion